Atara Biotherapeutics
ATRA
145 hedge funds and large institutions have $1.34B invested in Atara Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 48 increasing their positions, 53 reducing their positions, and 24 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
8% more capital invested
Capital invested by funds: $1.24B → $1.34B (+$93.4M)
0.05% less ownership
Funds ownership: 4.15% → 4.09% (-0.05%)
2% less call options, than puts
Call options by funds: $426K | Put options by funds: $436K
9% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 53
4% less funds holding
Funds holding: 151 → 145 (-6)
25% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$21.4M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
+$13.8M |
| 3 |
JP Morgan Chase
New York
|
+$11.5M |
| 4 |
BlackRock
New York
|
+$11M |
| 5 |
Goldman Sachs
New York
|
+$6.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$24M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$18.9M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$18.2M |
| 4 |
AG
Artal Group
Luxembourg
|
-$7.13M |
| 5 |
Two Sigma Investments
New York
|
-$6.74M |
ATRA Hedge Fund Activity: Q2 2021 in Review
145 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2021, worth a combined $1.34B — up 7.5% from $1.24B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ATRA and 18 opened new positions — a net loss of 6 holders — while 53 trimmed existing stakes and 48 added.
The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $21.4M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $24M sold.
- 145 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2021, down from 151 in Q1 2021.
- Funds reported $1.34B of Atara Biotherapeutics stock for Q2 2021, up 7.5% quarter-over-quarter.
- 18 funds opened new Atara Biotherapeutics positions in Q2 2021 and 24 closed out, a net change of -6 holders.
- The largest Atara Biotherapeutics buyer in Q2 2021 was Assenagon Asset Management, an estimated $21.4M added.
- The largest Atara Biotherapeutics seller in Q2 2021 was Consonance Capital Management, an estimated $24M sold.
Based on aggregated 13F filings for Q2 2021.